Immunizations
Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Vaccinating one million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent thousands of hospitalizations over two seasons of the virus, according to a Centers for Disease Control and Prevention analysis. A CDC medical officer presented the analysis, […]
Read More
CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults 60 and older
A health worker prepares a flu vaccine shot before administering it to a local resident in Los Angeles, the United States, on Dec. 17, 2022. Xinhua News Agency | Getty Images An advisory committee to the Centers for Disease Control and Prevention on Wednesday recommended that adults ages 60 and above, after consulting their doctors, […]
Read More
GSK says RSV vaccine for older adults provides protection over two seasons
Respiratory syncytial virus viral vaccine under research. Hailshadow | Istock | Getty Images GlaxoSmithKline on Wednesday said its vaccine to protect adults ages 60 and older from respiratory syncytial virus, or RSV, remained effective across two seasons of the disease. A single dose of the shot was 67.2% effective in preventing lower respiratory tract illness […]
Read More
Pfizer RSV vaccine for older adults is only slightly less effective after 18 months
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images Pfizer‘s vaccine that protects adults ages 60 and older from respiratory syncytial virus was slightly less effective after 18 months, according to clinical trial results the company announced Wednesday. The data is from New York-based Pfizer’s clinical trial on more than […]
Read More
Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head start
A pharmacist prepares to administer COVID-19 vaccine booster shots during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center on September 09, 2022 in Chicago, Illinois. Scott Olson | Getty Images The U.S. Food and Drug Administration’s Covid strain selection for the next round of shots puts Pfizer, Moderna […]
Read More
FDA advisors recommend that new Covid vaccines target an omicron XBB variant this fall
A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022. Johanna Geron | Reuters The U.S. Food and Drug Administration’s independent panel of advisors on Thursday recommended that updated Covid shots for the fall and winter target one of the XBB variants, […]
Read More
Covid vaccine maker Novavax sees a pathway to survival – but it won’t be easy
Medical syringes and Novavax logo displayed in the background are seen in this illustration photo taken in Krakow, Poland on December 2, 2021. Jakub Porzycki | NurPhoto | Getty Images Novavax has a clear message for Wall Street: The cash-strapped Covid vaccine maker sees a pathway to survival. Maryland-based Novavax said as much last month […]
Read More
Here’s what Pfizer and Moderna say is subsequent for their Covid vaccines
A pharmacist prepares to administer COVID-19 vaccine booster pictures through an function hosted by the Chicago Division of Public Health and fitness at the Southwest Senior Middle on September 09, 2022 in Chicago, Illinois. Scott Olson | Getty Pictures 3 several years and billions of Covid vaccinations into the pandemic, Pfizer and Moderna say their […]
Read More
FDA advisors recommend Pfizer’s RSV vaccine for infants but raise safety concerns
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images The Food and Drug Administration’s independent panel of advisors on Thursday recommended full approval of Pfizer’s vaccine that protects infants from RSV, but raised safety concerns over premature births that may be tied to the shot. The committee unanimously said the […]
Read More
Pfizer RSV vaccine for infants has ‘generally favorable’ safety data, FDA staff say
Blood sample for respiratory syncytial virus (RSV) test Jarun011 | Istock | Getty Images U.S. Food and Drug Administration staff on Tuesday said Pfizer’s vaccine that protects infants from respiratory syncytial virus has “generally favorable” safety data. The FDA staff made the conclusion in briefing documents ahead of a meeting on Thursday, when a panel […]
Read More